MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Position in Axon Enterprise, Inc. (NASDAQ:AXON)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 557.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 76,311 shares of the biotechnology company's stock after purchasing an additional 64,708 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.10% of Axon Enterprise worth $45,353,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of AXON. Capital World Investors increased its stake in shares of Axon Enterprise by 86.4% during the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after acquiring an additional 841,772 shares during the period. Alliancebernstein L.P. increased its stake in shares of Axon Enterprise by 273.8% during the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock worth $659,128,000 after acquiring an additional 812,337 shares during the period. Norges Bank acquired a new position in shares of Axon Enterprise during the fourth quarter worth about $482,081,000. GQG Partners LLC acquired a new position in shares of Axon Enterprise during the fourth quarter worth about $478,349,000. Finally, Vanguard Group Inc. increased its stake in shares of Axon Enterprise by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock worth $5,019,886,000 after acquiring an additional 275,959 shares during the period. Institutional investors and hedge funds own 79.08% of the company's stock.

Axon Enterprise Price Performance

Shares of NASDAQ AXON traded up $4.79 on Friday, hitting $733.18. The company's stock had a trading volume of 419,101 shares, compared to its average volume of 759,084. Axon Enterprise, Inc. has a 12-month low of $273.52 and a 12-month high of $735.68. The company has a market capitalization of $57.08 billion, a price-to-earnings ratio of 189.45, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The stock has a 50 day moving average of $584.61 and a 200-day moving average of $593.44.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The company had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the prior year, the firm earned $1.15 earnings per share. The company's revenue for the quarter was up 31.3% compared to the same quarter last year. As a group, research analysts predict that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Wall Street Analysts Forecast Growth

AXON has been the topic of a number of recent analyst reports. Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Northcoast Research lowered shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Barclays boosted their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Needham & Company LLC boosted their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Finally, The Goldman Sachs Group boosted their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $652.73.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 307 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the sale, the director now owns 1,627 shares of the company's stock, valued at $899,275.44. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brittany Bagley sold 3,400 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $700.00, for a total transaction of $2,380,000.00. Following the transaction, the chief financial officer now directly owns 131,833 shares in the company, valued at $92,283,100. The trade was a 2.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,764 shares of company stock valued at $14,856,635 over the last quarter. Corporate insiders own 4.40% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.